AMP Capital Investors Ltd decreased its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 1.0% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 128,910 shares of the biotechnology company’s stock after selling 1,247 shares during the quarter. AMP Capital Investors Ltd owned 0.07% of BioMarin Pharmaceutical worth $11,998,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Cigna Investments Inc. New grew its stake in shares of BioMarin Pharmaceutical by 1.5% during the 2nd quarter. Cigna Investments Inc. New now owns 2,377 shares of the biotechnology company’s stock valued at $216,000 after purchasing an additional 36 shares during the period. Daiwa Securities Group Inc. grew its stake in shares of BioMarin Pharmaceutical by 1.0% during the 2nd quarter. Daiwa Securities Group Inc. now owns 4,950 shares of the biotechnology company’s stock valued at $450,000 after purchasing an additional 50 shares during the period. Ameritas Investment Partners Inc. grew its stake in shares of BioMarin Pharmaceutical by 1.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,126 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 54 shares during the period. NGAM Advisors L.P. grew its stake in shares of BioMarin Pharmaceutical by 0.4% during the 2nd quarter. NGAM Advisors L.P. now owns 15,245 shares of the biotechnology company’s stock valued at $1,385,000 after purchasing an additional 55 shares during the period. Finally, Symphony Asset Management LLC grew its stake in shares of BioMarin Pharmaceutical by 1.1% during the 2nd quarter. Symphony Asset Management LLC now owns 6,465 shares of the biotechnology company’s stock valued at $587,000 after purchasing an additional 73 shares during the period. 99.25% of the stock is owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Inc. (BMRN) opened at $81.99 on Monday. The company has a current ratio of 4.91, a quick ratio of 3.81 and a debt-to-equity ratio of 0.41. BioMarin Pharmaceutical Inc. has a 52 week low of $80.10 and a 52 week high of $100.51.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings data on Thursday, October 26th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.06. BioMarin Pharmaceutical had a negative return on equity of 4.60% and a negative net margin of 12.45%. The company had revenue of $334.18 million during the quarter, compared to the consensus estimate of $347.38 million. During the same period in the previous year, the company posted $0.02 EPS. The firm’s revenue was up 19.4% on a year-over-year basis. research analysts predict that BioMarin Pharmaceutical Inc. will post -0.65 earnings per share for the current fiscal year.

In related news, EVP George Eric Davis sold 1,200 shares of the business’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $85.64, for a total value of $102,768.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Jeffrey Robert Ajer sold 3,521 shares of the business’s stock in a transaction that occurred on Friday, September 22nd. The stock was sold at an average price of $95.00, for a total value of $334,495.00. Following the completion of the transaction, the executive vice president now directly owns 49,299 shares in the company, valued at $4,683,405. The disclosure for this sale can be found here. Over the last three months, insiders sold 41,886 shares of company stock worth $3,839,086. 1.85% of the stock is owned by insiders.

BMRN has been the subject of a number of recent research reports. Evercore ISI initiated coverage on BioMarin Pharmaceutical in a research note on Wednesday, August 16th. They set an “outperform” rating and a $100.00 price target for the company. BidaskClub downgraded BioMarin Pharmaceutical from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 17th. Jefferies Group set a $116.00 price target on BioMarin Pharmaceutical and gave the company a “buy” rating in a research note on Friday, August 25th. Citigroup initiated coverage on BioMarin Pharmaceutical in a research note on Thursday, August 31st. They set a “buy” rating and a $98.00 price target for the company. Finally, Piper Jaffray Companies initiated coverage on BioMarin Pharmaceutical in a research note on Thursday, September 14th. They set an “overweight” rating and a $113.00 price target for the company. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and sixteen have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $111.70.

TRADEMARK VIOLATION NOTICE: “BioMarin Pharmaceutical Inc. (BMRN) Holdings Trimmed by AMP Capital Investors Ltd” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/biomarin-pharmaceutical-inc-bmrn-holdings-trimmed-by-amp-capital-investors-ltd/1756844.html.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.